10 Small–Cap Stocks Insiders Are Selling Recently

4. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of insiders selling: 8

Market capitalization: $1.032B

Intellia Therapeutics is a clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company is focused on developing new treatments for both in vivo and ex vivo applications. Its flagship program, NTLA-2011 is focused on treating transthyretin amyloidosis, which is currently an incurable disease. Intellia also has various other programs in its pipeline that are in different trial stages.

In January, eight insiders, including President and CEO, sold a total of approximately $833,916 worth of Intellia shares, at an average price of $11.92. The stock is currently trading at $9.64, having declined 17.32% year-to-date.

As many as 20 Wall Street analysts have an average “Strong Buy,” rating on Intellia stock, and the price target is $43.44, with the highest forecast of $91.00 and the lowest at $11.00, according to data from TipRanks. The average price forecast represents a 350.62% change from the last price of $9.64.

On January 27, Morgan Stanley downgraded Intellia Therapeutics stock from “Overweight” to “Equal Weight”, and also considerably lowered its price target – from $56 to $11. Morgan Stanley noted huge competition from alternative therapies that do not involve gene editing.

For the third quarter of 2024, Intellia reported collaboration revenue was $9.1 million compared to $12.0 during the third quarter of 2023. The $2.9 million decrease was mainly driven by a reduction in revenue related to the AvenCell license and collaboration agreement. Net loss for the quarter was $135.7 million, compared to $122.2 million during the third quarter of 2023.

Intellia Therapeutics is also one of Cathie Wood’s Stock Portfolio: 2025 Stock Picks.